Skip to main content
. 2023 Jun 28;62(9):1231–1241. doi: 10.1007/s40262-023-01262-2

Table 4.

Plasma concentration–time data for difelikefalin and metabolites (pooled samples by time point)

Healthy subjects
Time (h)
Analyte 0.0 0.083 0.25 0.5 1 2 4 6a 8a 12a 24a 36a 48a
Difelikefalin 0.00 23.8 16.9 12.6 9.17 6.01 3.22
MP1 0.00 0.356 0.269 0.351 b b b
MP2 0.00 0.166 b b b b b
MP3 0.00 0.282 b b b b b
MP4 0.00 0.141 b b b b b
Total 0.00 24.7 17.2 13.0 9.17 6.01 3.22
Subjects on hemodialysis
Time (h)
Analyte 0.0 0.083 0.25 0.5 1 2 4 6 8 12 24 36 48
Difelikefalin 0.00 24.7 16.6 14.2 11.8 10.8 9.33 8.46 7.81 6.99 5.22 4.17 3.06
MP1 0.00 0.548 0.344 0.242 0.159 b b b b b b b b
MP2 0.00 b b b b b b b b b b b b
MP3 0.00 0.340 0.249 b b b b b b b b b b
MP4 0.00 b b b b b b b b b b b b
Total 0.00 25.6 17.2 14.4 12.0 10.8 9.33 8.46 7.81 6.99 5.22 4.17 3.06

Concentrations reported in ng-eq/mL. Concentrations at pre-dose (0 h) were not determined; these were set to 0.00 ng-eq/mL during subsequent calculations

LC-RAD liquid-chromatography radiochromatogram

aTime point not included in metabolic profiling; in healthy subjects, samples from 0–4 h contained 98% of the plasma radioactivity

bCharacterization of some peaks in LC–RAD spectra (MP1, MP2, MP3, and MP4, found at less than 0.6 ng-eq/mL at any given time point) were not undertaken due to their low relative peak area